Bayer HealthCare to improve production capability in China significantly Bayer HealthCare can invest around EUR 100 million to improve the production capability of its plant in Beijing significantly, China, in preparation for additional demand of its items in the national nation. A respective contract was signed in Germany on the event of the go to of the President of the People’s Republic of China, Xi Jinping, by the CEO of Bayer AG, Dr Marijn Dekkers. The planned capacity growth is made to ensure a dependable supply of high-quality items to meet up the domestic demand for Bayer HealthCare’s products like the company’s cardiovascular and anti-diabetes products generic orlistat . The expansion includes logistics areas for automatic material handling fully, analytical laboratories, and high-speed product packaging lines.
Bayer HealthCare to provide outcomes on investigational oncology substances at ASCO annual meeting Bayer Health care Pharmaceuticals, Inc. Announced today that data evaluating many of its investigational oncology substances will be shown in a scientific discussion board at the 2011 Annual Interacting with of the American Culture of Clinical Oncology , 3-7 June, in Chicago, IL.S. Food and Medication Administration , the European Medicines Company or other Wellness Authorities.